Home Logon FTA Investment Managers Blog Subscribe About Us Contact Us

Search by Ticker, Keyword or CUSIP       
Blog Home
Bob Carey
Chief Market Strategist
X •  LinkedIn

  If You Can't Beat Them, Join Them!
Posted Under: Sectors
Supporting Image for Blog Post


View from the Observation Deck

  1. In our May 1st blog post (Biotech Pipelines and "Pharmerging Markets" offer Growth Potential) we discussed how pharmaceutical companies were making acquisitions and licensing agreements to build their drug pipelines.
  2. The 21st anniversary edition of Ernst & Young's "Beyond Borders: global biotechnology report 2007" revealed that 52% of biotech CEOs planned to partner with other firms to bring new products to market.
  3. In that same survey, 99% of American biotech CEOs and 87% of European biotech CEOs planned to seek alliances over the next two years. Alliances tend to be forged via licensing agreements.
  4. New data from Bloomberg supports those claims from 2007 (see chart). In addition, the number of deals surged after 2009.  
  5. While not included in the chart, the number of deals in Q1'12 totaled 73, the best showing for a first quarter since 2002.
Posted on Friday, May 18, 2012 @ 3:33 PM • Post Link Print this post Printer Friendly

These posts were prepared by First Trust Advisors L.P., and reflect the current opinion of the authors. They are based upon sources and data believed to be accurate and reliable. Opinions and forward looking statements expressed are subject to change without notice. This information does not constitute a solicitation or an offer to buy or sell any security.
Search Posts
Market Commentary and Analysis
Market Commentary Video
Monthly Talking Points
Quarterly Newsletter
Market Observations
Subscribe To Receive Email

Passive Investing More Popular Than Active Management Since 2007
Thinking about investing in Small-Caps?
Think about Micro-Caps.
The 6.1 Percent Solution
Money Market Fund (MMF) Shareholders Caught Between a Rock and a Hard Place!
Preferreds Offer Yield Spreads Similar To Speculative-Grade Debt
Biotech Pipelines and “Pharmerging Markets” offer Growth Potential
The Markets Fight Through the Headlines
China May Only Pose a Near-Term Challenge for Price of Copper
Agriculture Prices Take Breather Following Strong Decade
It’s Tough To Stay On Top!
Skip Navigation Links.
Search by Topic
Skip Navigation Links.

The information presented is not intended to constitute an investment recommendation for, or advice to, any specific person. By providing this information, First Trust is not undertaking to give advice in any fiduciary capacity within the meaning of ERISA, the Internal Revenue Code or any other regulatory framework. Financial professionals are responsible for evaluating investment risks independently and for exercising independent judgment in determining whether investments are appropriate for their clients.
Follow First Trust:  
First Trust Portfolios L.P.  Member SIPC and FINRA. (Form CRS)   •  First Trust Advisors L.P. (Form CRS)
Home |  Important Legal Information |  Privacy Policy |  California Privacy Policy |  Business Continuity Plan |  FINRA BrokerCheck
Copyright © 2024 All rights reserved.